Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Study

NCT04401527 is registered in ClinicalTrials.gov with Hope Pharmaceuticals as lead sponsor.

NCT NCT04401527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04401527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Study
Lead sponsor
Hope Pharmaceuticals
Phase
Phase 2
Overall status
Withdrawn
Start date
July 22, 2020
Completion date
August 15, 2020
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory distress syndrome, acute respiratory failure, covid-19